TRIP13-induced NUSAP1 upregulation promotes CcRCC progression through EMT and PI3K/AKT/mTOR pathway
TRIP13 is upregulated in ccRCC and may serve as a novel prognostic biomarker for patient survival and treatment response. Additionally, TRIP13 enhances ccRCC cell proliferation, invasion, and EMT via the PI3K/AKT/mTOR pathway, while its expression is closely linked to immune cell infiltration and immune checkpoint regulation, offering new insights for immunotherapeutic approaches in ccRCC.
Authors
- Kunyuan Huang
- Kehua Jiang (ORCID: https://orcid.org/0000-0002-9446-3158)
- Zhiqiang Zhu (ORCID: https://orcid.org/0009-0009-9003-0652)
- Fa Sun (ORCID: https://orcid.org/0000-0003-3556-0131)
- Peng Zheng (ORCID: https://orcid.org/0000-0002-9864-6832)
- Xiao‐Long Chen (ORCID: https://orcid.org/0000-0003-3796-9248)
- Qing Wang (ORCID: https://orcid.org/0000-0001-6540-1858)
- Kun Chen (ORCID: https://orcid.org/0000-0003-1162-6896)
- Guanyun Deng
Institutions
- Guiyang Medical University (CN)
- Guizhou University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Guizhou Provincial People's Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1186/s12967-025-06761-3
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China